Citations (39)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (12)
Francis Vekeman, R. Scott McKenzie, Brahim K. Bookhart, François Laliberté, Mei Sheng Duh, Catherine Tak Piech & Patrick Lefebvre. (2009) Drug utilisation and cost considerations of erythropoiesis stimulating agents in oncology patients receiving chemotherapy: observations from a large managed-care database. Journal of Medical Economics 12:1, pages 1-8.
Read now
Read now
Anil K Agarwal. (2008) Darbepoetin alfa for anemia in chronic kidney disease. Expert Review of Clinical Pharmacology 1:3, pages 369-379.
Read now
Read now
Robert J Rubin, John A Glaspy, John L Adams, Michael S Mafilios, Sharon M Wang, Hema N Viswanathan & Joel D Kallich. (2008) Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective. Journal of Medical Economics 11:2, pages 199-213.
Read now
Read now
Jeffrey Hymes, Tammy Bickimer, James H. Jackson, Brahim K. Bookhart, Samir H. Mody & Catherine Tak Piech. (2007) Dosing patterns, drug costs, and hematologic outcome in anemic patients with chronic kidney disease switching from darbepoetin alfa to epoetin alfa. Current Medical Research and Opinion 23:8, pages 1931-1937.
Read now
Read now
Frank J Papatheofanis. (2007) Comparative costs of treatment with epoetin alfa and darbepoetin alfa for anemia in the oncology and nephrology settings. Expert Review of Pharmacoeconomics & Outcomes Research 7:1, pages 59-73.
Read now
Read now
Paul Cornes, Bertrand Coiffier & Jean-Jacques Zambrowski. (2007) Erythropoietic therapy for the treatment of anemia in patients with cancer: a valuable clinical and economic option. Current Medical Research and Opinion 23:2, pages 357-368.
Read now
Read now
Frank J. Papatheofanis, R. Scott McKenzie, Samir H. Mody, Robert Y. Suruki & Catherine Tak Piech. (2006) Dosing patterns, hematologic outcomes, and costs of erythropoietic agents in predialysis chronic kidney disease patients with anemia. Current Medical Research and Opinion 22:5, pages 837-842.
Read now
Read now
R. Ben-Hamadi, M. S. Duh, J. Aggarwal, A. Henckler, R. S. McKenzie & C. Tak Piech. (2005) The cost-effectiveness of weekly epoetin alfa relative to weekly darbepoetin alfa in patients with chemotherapy-induced anemia. Current Medical Research and Opinion 21:10, pages 1677-1682.
Read now
Read now
Mei Sheng Duh & Tami L Mark. (2005) Cost–effectiveness of epoetin alfa and darbepoetin alfa in patients with chemotherapy-related anemia. Expert Review of Pharmacoeconomics & Outcomes Research 5:4, pages 383-394.
Read now
Read now
David H Henry. (2005) Epoetin alfa for the treatment of cancer- and chemotherapy-related anaemia: product review and update. Expert Opinion on Pharmacotherapy 6:2, pages 295-310.
Read now
Read now
Gordon J. Vanscoy. (2004) Comments on Clinical and economic comparison of epoetin alfa and darbepoetin alfa. Current Medical Research and Opinion 20:9, pages 1459-1463.
Read now
Read now
Gilbert Deray. (2004) Achieving therapeutic targets in renal anaemia: considering cost-efficacy. Current Medical Research and Opinion 20:7, pages 1095-1101.
Read now
Read now
Articles from other publishers (27)
Vicente Escudero-Vilaplana, Concepción Martínez-Nieto, Juan Manuel López-Gómez, Almudena Vega-Martínez, José María Bellón-Cano & María Sanjurjo-Sáez. (2013) Erythropoiesis-stimulating agents in anaemia due to chronic kidney disease: a cost-minimization analysis. International Journal of Clinical Pharmacy 35:3, pages 463-468.
Crossref
Crossref
Sihem Ait-Oudhia, An Vermeulen & Wojciech Krzyzanski. (2011) Non-linear mixed effect modeling of the time-variant disposition of erythropoietin in anemic cancer patients. Biopharmaceutics & Drug Disposition 32:1, pages 1-15.
Crossref
Crossref
Marie-Hélène Lafeuille, Robert A. Bailey, Francis Vekeman, Brett S. Kilpatrick, Mekré Senbetta, Catherine T. Piech & Patrick Lefebvre. (2010) Drug Utilization and Cost for Erythropoiesis-Stimulating Agents in a Long-Term Care Resident Population with Chronic Kidney Disease. The Consultant Pharmacist 25:8, pages 493-500.
Crossref
Crossref
A. MANGIA, O. DALGARD, N. MINERVA, H. VERBAAN, D. BACCA, H. RING-LARSEN, M. COPETTI, V. CARRETTA, V. PIAZZOLLA, R. COZZOLONGO, L. MOTTOLA & A. ANDRIULLI. (2010) Ribavirin dosage in patients with HCV genotypes 2 and 3 who completed short therapy with peg-interferon α-2b and ribavirin. Alimentary Pharmacology & Therapeutics 31:12, pages 1346-1353.
Crossref
Crossref
Florence Ranchon, Stéphanie Hédoux, Maurice Laville, Denis Fouque, Evelyne Decullier, François Chapuis & Laure Huot. (2010) Coût médical direct des agents stimulant l’érythropoïèse dans le traitement de l’anémie chez le patient insuffisant rénal chronique : revue de la littérature. Néphrologie & Thérapeutique 6:2, pages 97-104.
Crossref
Crossref
Shaffeeulah Bacchus, Neeta O'mara, Harold Manley & Steven Fishbane. (2009) Meeting New Challenges in the Management of Anemia of Chronic Kidney Disease Through Collaborative Care with Pharmacists. Annals of Pharmacotherapy 43:11, pages 1857-1866.
Crossref
Crossref
A. Sanz-Granda. (2009) Análisis probabilístico de minimización de costes de darbepoetin alfa frente a epoetina alfa en el tratamiento de la anemia secundaria a insuficiencia renal crónica. Valoración en la práctica clínica española. Farmacia Hospitalaria 33:4, pages 208-216.
Crossref
Crossref
A. Sanz-Granda. (2009) Probabilistic cost-minimisation analysis of darbepoetin alpha versus epoetin alpha in treating anaemia secondary to chronic renal failure. Assessment in Spanish clinical practice. Farmacia Hospitalaria (English Edition) 33:4, pages 208-216.
Crossref
Crossref
Mei Sheng Duh, Jennifer R Weiner, Leigh Ann White, Patrick Lefebvre & Paul E Greenberg. (2008) Management of Anaemia. PharmacoEconomics 26:2, pages 99-120.
Crossref
Crossref
Harminder Sikand, Adam Decter, Tina Greco, Sue H Watson, Yoon Jun KangSamir H ModyCatherine Tak PiechMei Sheng DuhAyesha Naeem. (2016) Cost Analytic Model to Determine the Least Costly Inpatient Erythropoiesis Stimulating Therapy Regimen. Annals of Pharmacotherapy 42:1, pages 16-23.
Crossref
Crossref
M. R. Nowrousian. 2008. Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology. Recombinant Human Erythropoietin (rhEPO) in Clinical Oncology
449
508
.
Raymond J. Muller & David Baribeault. (2007) Extended-dosage-interval regimens of erythropoietic agents in chemotherapy-induced anemia. American Journal of Health-System Pharmacy 64:24, pages 2547-2556.
Crossref
Crossref
Francis VekemanR. Scott McKenzie, Patrick Lefebvre, Sue H. Watson, Samir H. Mody, Catherine Tak Piech & Mei Sheng Duh. (2007) Dose and cost comparison of erythropoietic agents in the inpatient hospital setting. American Journal of Health-System Pharmacy 64:18, pages 1943-1949.
Crossref
Crossref
Anuprita Patkar, David Holdford, Donald F. Brophy & Michael Pyles. (2007) Off-Label Prescribing of Erythropoiesis-Stimulating Proteins in US Hospitals. Drug Information Journal 41:4, pages 431-440.
Crossref
Crossref
Frank Papatheofanis, Cynthia Smith, Samir Mody, R Scott McKenzie, Brahim Bookhart & Catherine Tak Piech. (2007) Dosing Patterns, Hematologic Outcomes, and Costs of Erythropoietic Agents in Anemic Predialysis Chronic Kidney Disease Patients From an Observational Study. American Journal of Therapeutics 14:4, pages 322-327.
Crossref
Crossref
Gernot Beutel & Arnold Ganser. (2007) Risks and Benefits of Erythropoiesis-Stimulating Agents in Cancer Management. Seminars in Hematology 44:3, pages 157-165.
Crossref
Crossref
Carsten Oberhoff. (2007) Speed of haemoglobin response in patients with cancer: a review of the erythropoietic proteins. Supportive Care in Cancer 15:6, pages 603-611.
Crossref
Crossref
John G. McHutchison, Michael P. Manns, Robert S. Brown, K. Rajender Reddy, Mitchell L. Shiffman & John B. Wong. (2007) Strategies for Managing Anemia in Hepatitis C Patients Undergoing Antiviral Therapy. The American Journal of Gastroenterology 102:4, pages 880-889.
Crossref
Crossref
David H. Henry. (2007) Epoetin Alfa Treatment for Patients with Chemotherapy-Induced Anemia. Supportive Cancer Therapy 4:2, pages 78-91.
Crossref
Crossref
J.B. Wish. (2006) The economic realities of erythropoiesis-stimulating agent therapy in kidney disease. Kidney International 70, pages S21-S25.
Crossref
Crossref
B. Reichardt. (2006) Cost comparison of epoetin alpha, epoetin beta and darbepoetin alpha for cancer patients with anaemia in the clinical practice setting*. Journal of Clinical Pharmacy and Therapeutics 31:5, pages 503-512.
Crossref
Crossref
Mei Sheng Duh, Samir H. Mody, R. Scott McKenzie, Patrick Lefebvre, Antoine Gosselin & Catherine Tak Piech. (2006) Dosing patterns and costs of erythropoietic agents in patients with chronic kidney disease not on dialysis in managed care organizations. Clinical Therapeutics 28:9, pages 1443-1450.
Crossref
Crossref
Julia Bohlius, Olaf Weingart, Sven Trelle & Andreas Engert. (2006) Cancer-related anemia and recombinant human erythropoietin—an updated overview. Nature Clinical Practice Oncology 3:3, pages 152-164.
Crossref
Crossref
Heinz Ludwig. (2006) Epoetin beta in oncology: examining the current evidence. Future Oncology 2:1, pages 21-38.
Crossref
Crossref
Mei Sheng Duh, Samir H Mody, R Scott McKenzie, Patrick Lefebvre, Antoine Gosselin, Brahim K Bookhart & Catherine Tak Piech. (2006) Dosing Patterns and Treatment Costs of Erythropoietic Agents in Elderly Patients with Pre-Dialysis Chronic Kidney Disease in Managed Care Organisations. Drugs & Aging 23:12, pages 969-976.
Crossref
Crossref
Robert J Cersosimo & Daniel R Jacobson. (2016) Epoetin Alfa Versus Darbepoetin Alfa in Chemotherapy-Related Anemia. Annals of Pharmacotherapy 40:1, pages 58-65.
Crossref
Crossref
Eric J. Kruep & Lorne E. Basskin. (2005) Cost-minimization analysis of darbepoetin alfa versus epoetin alfa in the hospital setting. American Journal of Health-System Pharmacy 62:24, pages 2597-2603.
Crossref
Crossref